A technological breakthrough in oral drug delivery.
A proprietary coating makes the capsule easy to swallow and keeps it intact through the esophagus. In the stomach, it dissolves to release the drug elements.
The drug-containing elements move freely in the stomach for a programmed duration, without interfering with any normal gastric processes.
The platform arms release a stable dose of drug over time that minimizes peaks and troughs.
At the desired timing the platform arms break off, allowing for natural passage out of the body.
Clinical Validation
The LYNX platform has been derisked with successful proof of concept data in multiple therapeutic areas, including a pivotal phase 3 study that demonstrated pharmacokinetic comparability to daily oral risperidone.
Study
The LYNX platform has been derisked with successful proof of concept data in multiple therapeutic areas, including a pivotal phase 3 study that demonstrated pharmacokinetic comparability to daily oral risperidone.
